Suppr超能文献

用于治疗HIV感染和艾滋病的体外全身热疗

Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS.

作者信息

Ash S R, Steinhart C R, Curfman M F, Gingrich C H, Sapir D A, Ash E L, Fausset J M, Yatvin M B

机构信息

HemoCleanse Inc., West Lafayette, Indiana 47906, USA.

出版信息

ASAIO J. 1997 Sep-Oct;43(5):M830-8.

PMID:9360163
Abstract

Whole body hyperthermia therapy (WBHT) is the elevation of the core body temperature to 42 degrees C. In vitro studies have confirmed that 42 degrees C is cytocidal for virally infected lymphocytes, and even more effective when heating is repeated 4 days later. The safety and efficacy of two successive sessions of WBHT (4 days apart) was evaluated in 30 patients with AIDS (not on protease inhibitors), randomized to: 1) untreated controls, 2) low temperature WBHT for 1 hour at 40 degrees C and repeated 96 hours later, and 3) high temperature WBHT for 1 hour at 42 degrees C and repeated 96 hours later. The sorbent suspension in the ThermoChem System (HemoCleanse, West Lafayette, IN) system automatically controlled blood phosphate, calcium, and other electrolyte concentrations during WBHT. In 1 year of follow-up after WBHT, there were positive effects of the therapy on frequency of AIDS defining events, Karnofsky score, and weight maintenance. However, effects on plasma HIV RNA and CD4 counts were transient. Two successive WBHT treatments were performed in four patients who were on protease inhibitor/triple drug therapy, but had suboptimal response. In follow-up for 6 months, plasma HIV RNA and CD4 improved after WBHT, and the patients remained clinically well. This WBHT may have specific advantages in patients with suboptimal response to protease inhibitor therapy.

摘要

全身热疗(WBHT)是将核心体温升高至42摄氏度。体外研究证实,42摄氏度对病毒感染的淋巴细胞具有细胞毒性,且在4天后重复加热时效果更佳。对30例艾滋病患者(未使用蛋白酶抑制剂)进行了两次连续WBHT(间隔4天)的安全性和疗效评估,这些患者被随机分为:1)未治疗对照组;2)在40摄氏度下进行1小时的低温WBHT,并在96小时后重复;3)在42摄氏度下进行1小时的高温WBHT,并在96小时后重复。ThermoChem系统(HemoCleanse,印第安纳州西拉斐特)中的吸附剂悬浮液在WBHT期间自动控制血液中的磷酸盐、钙和其他电解质浓度。在WBHT后的1年随访中,该疗法对艾滋病定义事件的发生频率、卡诺夫斯基评分和体重维持有积极影响。然而,对血浆HIV RNA和CD4计数的影响是短暂的。对4例正在接受蛋白酶抑制剂/三联药物治疗但反应欠佳的患者进行了两次连续的WBHT治疗。在6个月的随访中,WBHT后血浆HIV RNA和CD4有所改善,且患者临床状况良好。这种WBHT在对蛋白酶抑制剂治疗反应欠佳的患者中可能具有特定优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验